Baidu
map

同样是THA治疗,髋部骨折患者的术后发病率高于OA患者

2016-11-15 MedSci MedSci原创

接受全髋关节置换术(THA)治疗髋部骨折的患者,与接受全髋关节置换术治疗骨性关节炎(OA)的患者比较,术后并发症的风险增加。 全髋关节置换术是治疗髋关节退行性疾病的一种常规的外科手术方式。 David W. Fitz博士和他的同事们回顾了2011和2014年之间的国家外科质量改进计划数据,确定58302例接受THA治疗的OA患者,以及1580例接受THA治疗髋部骨折的患者。 研究

接受全髋关节置换术(THA)治疗髋部骨折的患者,与接受全髋关节置换术治疗骨性关节炎(OA)的患者比较,术后并发症的风险增加。

全髋关节置换术是治疗髋关节退行性疾病的一种常规的外科手术方式。

David W. Fitz博士和他的同事们回顾了2011和2014年之间的国家外科质量改进计划数据,确定58302例接受THA治疗的OA患者,以及1580例接受THA治疗髋部骨折的患者。

研究的主要结果包括CMS报告的并发症、非计划性再入院、手术后的住院时间和出院去向。

结果显示,OA患者和髋部骨折患者组的CMS报告的并发症发生率分别为4%和10.7%,出院后没有回到家中休养率分别为39.8%和64.7%,再入院率分别为39.8%和64.7%,术后平均住院时间分别为3.2%和4.4%。接受THA治疗髋部骨折的患者有更高的CMS报告的并发症、再入院风险。

原始出处:

Fitz D, et al. Differences in postoperative outcomes between total hip arthroplasty for fractures vs. osteoarthritis. Presented at: American Association of Hip and Knee Surgeons Annual Meeting; Nov. 10-13, 2016; Dallas.

THA for fracture associated with higher rates of morbidity than for OA.Healio.November 14, 2016

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1823297, encodeId=424f182329efb, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Sep 02 20:56:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=158797, encodeId=2344158e973a, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d5b1961515, createdName=1e13876fm02(暂无匿称), createdTime=Tue Nov 29 07:04:57 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408474, encodeId=5fc114084e4cd, content=<a href='/topic/show?id=92021020e814' target=_blank style='color:#2F92EE;'>#髋部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102078, encryptionId=92021020e814, topicName=髋部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=293f2750231, createdName=liuquan, createdTime=Thu Nov 17 10:56:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541165, encodeId=d5d2154116549, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Nov 17 10:56:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156021, encodeId=8d9c15602189, content=谢谢分享呀!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151102/IMG563643881070C8786.jpg, createdBy=f4241660247, createdName=小树, createdTime=Wed Nov 16 07:15:56 CST 2016, time=2016-11-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1823297, encodeId=424f182329efb, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Sep 02 20:56:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=158797, encodeId=2344158e973a, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d5b1961515, createdName=1e13876fm02(暂无匿称), createdTime=Tue Nov 29 07:04:57 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408474, encodeId=5fc114084e4cd, content=<a href='/topic/show?id=92021020e814' target=_blank style='color:#2F92EE;'>#髋部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102078, encryptionId=92021020e814, topicName=髋部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=293f2750231, createdName=liuquan, createdTime=Thu Nov 17 10:56:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541165, encodeId=d5d2154116549, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Nov 17 10:56:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156021, encodeId=8d9c15602189, content=谢谢分享呀!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151102/IMG563643881070C8786.jpg, createdBy=f4241660247, createdName=小树, createdTime=Wed Nov 16 07:15:56 CST 2016, time=2016-11-16, status=1, ipAttribution=)]
    2016-11-29 1e13876fm02(暂无匿称)

    学习了,谢谢。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1823297, encodeId=424f182329efb, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Sep 02 20:56:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=158797, encodeId=2344158e973a, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d5b1961515, createdName=1e13876fm02(暂无匿称), createdTime=Tue Nov 29 07:04:57 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408474, encodeId=5fc114084e4cd, content=<a href='/topic/show?id=92021020e814' target=_blank style='color:#2F92EE;'>#髋部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102078, encryptionId=92021020e814, topicName=髋部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=293f2750231, createdName=liuquan, createdTime=Thu Nov 17 10:56:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541165, encodeId=d5d2154116549, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Nov 17 10:56:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156021, encodeId=8d9c15602189, content=谢谢分享呀!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151102/IMG563643881070C8786.jpg, createdBy=f4241660247, createdName=小树, createdTime=Wed Nov 16 07:15:56 CST 2016, time=2016-11-16, status=1, ipAttribution=)]
    2016-11-17 liuquan
  4. [GetPortalCommentsPageByObjectIdResponse(id=1823297, encodeId=424f182329efb, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Sep 02 20:56:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=158797, encodeId=2344158e973a, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d5b1961515, createdName=1e13876fm02(暂无匿称), createdTime=Tue Nov 29 07:04:57 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408474, encodeId=5fc114084e4cd, content=<a href='/topic/show?id=92021020e814' target=_blank style='color:#2F92EE;'>#髋部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102078, encryptionId=92021020e814, topicName=髋部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=293f2750231, createdName=liuquan, createdTime=Thu Nov 17 10:56:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541165, encodeId=d5d2154116549, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Nov 17 10:56:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156021, encodeId=8d9c15602189, content=谢谢分享呀!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151102/IMG563643881070C8786.jpg, createdBy=f4241660247, createdName=小树, createdTime=Wed Nov 16 07:15:56 CST 2016, time=2016-11-16, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1823297, encodeId=424f182329efb, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Sat Sep 02 20:56:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=158797, encodeId=2344158e973a, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3d5b1961515, createdName=1e13876fm02(暂无匿称), createdTime=Tue Nov 29 07:04:57 CST 2016, time=2016-11-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1408474, encodeId=5fc114084e4cd, content=<a href='/topic/show?id=92021020e814' target=_blank style='color:#2F92EE;'>#髋部#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102078, encryptionId=92021020e814, topicName=髋部)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=293f2750231, createdName=liuquan, createdTime=Thu Nov 17 10:56:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541165, encodeId=d5d2154116549, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Thu Nov 17 10:56:00 CST 2016, time=2016-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=156021, encodeId=8d9c15602189, content=谢谢分享呀!, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151102/IMG563643881070C8786.jpg, createdBy=f4241660247, createdName=小树, createdTime=Wed Nov 16 07:15:56 CST 2016, time=2016-11-16, status=1, ipAttribution=)]
    2016-11-16 小树

    谢谢分享呀!

    0

相关资讯

J Arthroplasty:布比卡因脂质体可有效管理THA患者的术后疼痛问题

虽然疼痛管理影响康复,住院时间和功能结果,但是目前尚未有标准化的最佳的疼痛管理策略。阿片类药物是用于控制急性术后疼痛的主要药物,但是阿片类药物存在诸多副作用。布比卡因脂质体(LB)是一种长效镇痛剂,可控制术后疼痛长达72小时而不影响患者的运动功能。研究共纳入686名初次接受全髋关节置换(THA)的患者,均接受标准的疼痛管理,另外纳入586名初次接受THA的患者作为对比,这些患者术中注射LB作为额外

AAOS 2013:THA,TKA治疗后患者性功能改善明显

  THA, TKA治疗后患者性功能改善明显   ——较多女性患者报告术后性功能改善   髋关节炎、膝关节炎会限制正常性生活,每年有数百万美国人遭受髋关节炎或膝关节炎的摧残。据B学术厅展示的023号科学壁报展示的研究结果显示,90%的患者在接受全髋关节置换术(THA)或全膝关节置换术(TKA)后性功能得到了改善。   此研究包含70岁以下,计划接受一期THA或一期TKA的患者147名。所有患

AAOS 2013:全髋关节置换术(THA)前路与后路手术疗效相似

  2013年美国骨科医生学会年会(AAOS)于3月19-23日在美国芝加哥隆重召开。来自大会上的一项报告资料显示,尽管经后路(PA)全髋关节置换术(THA)术后关节活动度和力量得到改善,但PA和直接前路(DAA)THA恢复模式相似。   对于学术报告(编号043)中提到的“直接前路和经后路全髋关节置换术的步态参数改善相似” ,作者解释说,PA组步态速率显著改善,随访6个月和12月时,

AAOS 2013:≤55岁全髋关节置换术(THA)患者翻修失败率更高

  2013年美国医师学会年会(AAOS)于3月19日隆重召开。在21日大会上报告的一项研究显示,≤55岁患者全髋关节置换术(THA)翻修失败率显著高于同年龄段初次THA者。   “越年轻越有活力的患者接受初次THA,其植入失败风险和后期翻修手术风险会增加,”圣路易斯华盛顿大学医学院(WUSM)Muyibat A. Adelani博士指出。Adelani博士及其同事试图确定这

J Arthroplasty:TJA前无需常规进行牙齿的清洁准备

全关节置换术后的假体感染是灾难性的。最为常见的感染来源是手术过程中在切口内的细菌定植,其他如血源性等也可发生。考虑到假体感染后的灾难性后果,在术前做足预防措施并不为过。 牙齿疼痛是临床中较为常见的情形,通常这一症状可能预示着牙齿的感染,既往有研究认为,牙源性感染的高发生率对关节置换术是一个潜在的感染威胁,因此有医生要求,对择期关节置换的患者,最好在术前可以进行牙齿方面的清洁准备,但事实上

JBJS:30岁以下现代陶瓷对聚乙烯全髋置换中期疗效良好

全髋关节置换(THA)术后会因聚乙烯衬垫磨损导致假体无菌性松动和骨溶解并带来失败,对这一问题的担心限制了THA在年轻患者中的应用。 但过去10年中材料设计制造的进步已经大大提高了假体的磨损特性,不少研究已经提示新型高交链聚乙烯衬垫的磨损量明显低于传统的普通聚乙烯衬垫。但多数研究的术后随访期限均小于10年,且缺乏支持高交链聚乙烯衬垫用于30岁以下病例的临床和影像学证据。 假体界面配对

Baidu
map
Baidu
map
Baidu
map